With treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now, Uniqure has decided to terminate post-marketing studies required for prolongation of its existing EU conditional market approval.
Synthetic promoter and gene expression specialist Synpromics has completed a £5.2m (€6.2m) financing round with existing investors.
Autoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares (ADSs) in an follow-on offering led by Morgan Stanley at $90 per ADS.
Irish Allergan and Swiss Novartis have agreed to start a proof-of-concept study of a combination of their NASH candidates cenicriviroc (Allergan) and FXR agonist LJN452 (Novartis).
sphingotec GmbH and bestbion dx GmbH have signed an agreement to market sphingotecs innovative sepsis and congestive heart failure test (sphingotest bio-ADM) and acute kidney function monitoring assay (sphingotest penKid) in Germany and Austria.
Following its CHF1.901bn IPO at SIX Swiss Exchange on 7 April, Galenica Santé has announced full excercise of the over-allotment option worth CHF248m.
Spanish Economy Minister Luis de Guindos and EMBL Director-General Iain Mattaj have inked an agreement to host a world-class tissue imaging facility in Barcelona. The EMBLs 6th site in Europe will start work in September.
After having received market authorisation in Europe and the US for alectinib as second-line treatment for ALK-positive NSCLC, Roche presents data that qualifies the oral drug as first-line therapy.
French cancer specialist Nanobiotix has closed a €25.1m placement of shares being issued to qualified and institutional investors in the US and Europe. The company will use to funds go push commercialisation of its lead candidate NBTXR3.
As cancer immune therapy specialist Adaptimmunes R&D pipeline has expanded from 9 to 11 candidates and R&D cost rose from US$40.5m to US$63.8m, the company needed more funds.